ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor that is highly potent in human whole blood assay and can suppress inflammation caused by the NLRP3 inflammasome, , zydus, NLRP3 inhibitor, ZYIL1, Amyotrophic Lateral Sclerosis (ALS)